Table 1. Baseline characteristics of the study participants. Values are means (±SE) or counts (%). |
|
DHA
(n=14) |
Placebo
(n=13) |
Between-group
P-value |
| Age, yr |
31.9 (3.1) |
33.3 (2.4 |
.73 |
| Height, m |
1.63 (.02) |
1.68 (.01) |
.07 |
| Weight, kg |
60.3 (2.8) |
66.1 (4.8) |
.30 |
| BMI, kg·m-2 |
22.7 (1.1) |
23.5 (1.6) |
.67 |
| 1RM, kg |
6.1 (.3) |
6.5 (.4) |
.39 |
| 120% 1RM, kg |
7.3 (.4) |
7.8 (.4) |
.39 |
| Active participation in strength training, number of subjects |
0 (0%) |
0 (0%) |
1.00 |
| Active participation in endurance exercise training, number of subjects |
5 (36%) |
2 (15%) |
.24 |
| *Frequency endurance exercise, sessions/week |
3(2) |
3(2) |
.54 |
| Pill Compliance (%) |
94 (2.7) |
95 (1.9) |
.84 |
|
BMI, body mass index; 1RM, one repetition maximum. Between-group p-values are from independent t-tests for quantitative data or Fisher’s exact tests for frequencies. |
|